Emirates NBD's Ed Bell on the impact of sub-$60 oil
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enhancing drug accessibility. However, challenges such as low adherence and rural access remain. Key market players include Amgen, Eli Lilly, and Pfizer. Saudi Arabian Osteoporosis Drugs Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Osteoporosis Drugs Market to Reach US$ 308.84 Million by 2033 - 4.33% CAGR Driven by Biologics and Aging Population" report has been added to Saudi Arabia Osteoporosis Drugs Market is expected to reach US$ 308.84 million by 2033 from US$ 210.89 million in 2024, with a CAGR of 4.33% from 2025 to 2033 Due to improved healthcare infrastructure, the Saudi Arabian market for osteoporosis medications is concentrated in urban areas like Riyadh, Jeddah, and Dammam, whereas rural areas have less access to experts, diagnostics, and treatment alternatives. Growing rates of osteoporosis, the quick uptake of biologics, and advantageous healthcare laws in a number of Saudi Arabian nations are the main causes of this expansion. While bisphosphonates continue to dominate in volume due to their cost effectiveness, the biologics segment is anticipated to grow at the quickest rate. Government programs under Vision 2030, which prioritize regional medication production and improved healthcare infrastructure, promote the pharmaceutical industry. Osteoporosis treatments are becoming more accessible and reasonably priced as a result of these initiatives, and both name brand and generic medications are essential in satisfying the rising calcitonin, parathyroid hormone analogs, selective estrogen receptor modulators (SERMs), and monoclonal antibodies are among the available treatments. Newer biologic medicines are steadily gaining traction because of their increased efficacy and better patient outcomes, even if bisphosphonates are still frequently administered. Despite progress, issues like poor drug adherence, low awareness in rural regions, and underdiagnosis still exist. Additionally, comprehensive nationwide screening programs and coordinated post fracture care are lacking. Reducing the long term economic cost of osteoporosis in the nation and improving treatment outcomes could be achieved by addressing these challenges through integrated care models, digital health technologies, and Factors Driving the Saudi Arabia Osteoporosis Drugs Market Growth Saudi Arabia's Aging Population Is GrowingBecause osteoporosis and aging are closely related, Saudi Arabia's aging population is a major factor driving up demand for osteoporosis medications. People are more susceptible to fractures, loss of bone density, and associated problems as they get older, especially those over?60. The need for long term therapeutic treatments as well as preventive measures is growing as a result of this demographic shift. More people are reaching the age range where osteoporosis becomes a major concern due to better healthcare and longer life expectancies. As a result, the incidence of osteoporosis is rising in areas with greater populations of elderly persons. In order to assist the aging population and lessen the health burden associated with fractures, this development emphasizes the urgent need for efficient drugs and healthcare Rates of Screening and DiagnosisEarly osteoporosis identification has increased throughout Saudi Arabia thanks to the availability of sophisticated diagnostic technologies including dual energy X ray absorptiometry (DEXA) and bone mineral density (BMD) scanning. These technologies are now widely used in hospitals and clinics, increasing screening accessibility for high risk populations, especially postmenopausal women. In order to encourage early testing and diagnosis, health authorities are aggressively promoting awareness and screening initiatives. Because of this, more people are being diagnosed with bone loss early on, when treatment can be most successful. The number of patients eligible for osteoporosis treatments has increased dramatically due to the increase in early detection, which has increased demand for pharmacological interventions and made it possible to control the condition more effectively over the long Initiated Medical ProgramsAs a national health issue, osteoporosis is being actively addressed by the Saudi Arabian government. It seeks to lower the frequency of fractures and enhance bone health outcomes through education programs, public health campaigns, and preventative measures. Osteoporosis screening and bone density monitoring are becoming more commonplace in national health programs, and access to therapies is being facilitated by drug reimbursement policies and subsidized treatment options. These programs are promoting earlier medical intervention and increasing treatment adherence. Additionally, by making strategic investments in public health, the government's Vision 2030 push for local pharmaceutical development and a larger healthcare infrastructure is bolstering the availability of osteoporosis medications and promoting long term market in the Saudi Arabia Osteoporosis Drugs Market Low Persistence and Adherence to TreatmentLow patient adherence and persistence with prescribed medication regimens is one of the main issues facing Saudi Arabia's osteoporosis management. A lack of immediate, apparent benefits, worries about long term health repercussions, or worries about adverse effects cause many patients to stop treatment too soon. Non-adherence is also influenced by cultural norms and a lack of knowledge about how osteoporosis progresses. Treatment results are harmed as a result, raising the risk of fractures and associated problems. Long term patient involvement is challenging for healthcare practitioners, particularly when patients need daily or weekly oral medication. Enhancing patient education, providing alternate dosage regimens, and incorporating follow up assistance may all contribute to increased adherence and improved population wide therapeutic Treatment Persistence and AdherencePoor patient perseverance and adherence to prescribed treatment regimens is one of the main issues facing osteoporosis care in Saudi Arabia. Due to worries about side effects, worries about long term health repercussions, or a lack of obvious, immediate advantages, many patients stop treatment too soon. Non-adherence is further exacerbated by cultural attitudes and a lack of knowledge regarding the progressive nature of osteoporosis. Treatment results suffer as a result, and the risk of fractures and associated complications rises. It can be challenging for healthcare professionals to stay in touch with patients over the long term, particularly when they need daily or weekly oral medication. Enhancing follow up assistance, providing alternate dose schedules, and improving patient education may all contribute to increased adherence and improved therapeutic efficacy for the general public. Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Amgen Inc. Eli Lilly and Company F. Hoffmann La Roche AG GlaxoSmithKline Plc Merck & Co. Inc. Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Ltd. UCB S.A. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $210.89 Million Forecasted Market Value (USD) by 2033 $308.84 Million Compound Annual Growth Rate 4.3% Regions Covered Saudi Arabia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia Osteoporosis Drugs Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Route of Administration6.3 By States7. Product Type7.1 Bisphosphonates7.2 Calcitonin7.3 Rank Ligand Inhibitor7.4 Parathyroid Hormone Therapy (PTH)7.5 Selective Estrogen Receptor Modulators (SERMs)7.6 Sclerostin Inhibitor7.7 Others8. Route of Administration8.1 Oral8.2 Injectable8.3 Others9. Top States9.1 Dhahran9.2 Riyadh9.3 Khobar9.4 Jeddah9.5 Dammam9.6 Others10. Value Chain Analysis11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Pricing Benchmark Analysis13.1 Amgen Inc.13.2 Eli Lilly and Company13.3 F. Hoffmann-La Roche AG13.4 GlaxoSmithKline Plc13.5 Merck & Co. Inc.13.6 Novartis AG13.7 Pfizer Inc.13.8 Teva Pharmaceutical Industries Ltd.13.9 UCB S.A.14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Osteoporosis Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Forbes
18 hours ago
- Forbes
Middle East's $1.5 Trillion Secret: 5 Rules To Generational Wealth
"When the winds of change blow, some build walls, others build windmills." That ancient proverb captures the mindset of American investors eyeing the Middle East as a global growth engine. Over the past decade, Saudi Arabia and the UAE have emerged as two of the world's most ambitious economies. Fueled by trillion-dollar sovereign wealth funds, visionary transformation plans, and an urgent push to diversify beyond oil, these Gulf states are redefining global investing. The Opportunity: Reform Meets Capital Saudi Arabia's Vision 2030 aims to pivot the Kingdom from oil dependence to a diversified economy powered by tourism, technology, and private enterprise. Flagship projects like NEOM—a $500 billion smart city—exemplify this ambition. Behind this push is the Public Investment Fund (PIF), Saudi Arabia's $900 billion sovereign wealth fund, now one of the world's most influential capital allocators. The UAE has positioned itself as the Middle East's financial and innovation hub. The Abu Dhabi Investment Authority and Mubadala, with combined assets over $1.5 trillion, actively co-invest with foreign companies entering the region. Why U.S. Investors Are Paying Attention Three forces are drawing U.S. capital toward the Gulf: Capital-Rich Ecosystems: Saudi and Emirati leaders eagerly seek global expertise through joint ventures and strategic partnerships. Demographics: Nearly two-thirds of the population is under 35, driving demand across education, healthcare, tech, and consumer services. Stability: While Western markets face uncertainty, the Gulf offers centralized control and long-term stability with sovereign funds that think in decades. How to Win: Five Principles for Success 1. Play the Long Game: Relationships matter and trust takes time. Patient investors with local presence outperform those chasing quick wins. 2. Find the Right Local Partner: Local alignment is non-negotiable for navigating regulations and accessing opportunities. 3. Understand the Vision: Every investment is evaluated through national development plans. Align with Vision 2030 goals or UAE innovation strategies. 4. Respect the Culture: Business is personal. Trust is earned over time through shared experiences and repeated engagement. 5. Bring More Than Capital: Money is abundant; execution is scarce. Bring operating expertise, technology, or global networks. Key Sectors of Interest Target sectors aligned with regional transformation: The Bottom Line The Middle East runs on different rules: patience over speed, partnership over pitch, purpose over profit. For U.S. investors willing to engage deeply and align with national goals, the rewards could be generational. As Gulf nations transform themselves, they're reshaping the global investment landscape.
Yahoo
20 hours ago
- Yahoo
PwC India plans to create 20,000 additional jobs in next five years
PwC India has unveiled plans to increase its employee base to 50,000 over the next five years with the creation of 20,000 new jobs. The company announced its Vision 2030 approach with a target of tripling its revenue within five years. This plan includes a commitment to invest more than 5% of annual revenues in technology and innovation. The firm intends to concentrate on several key areas, such as digital transformation, sustainability, risk management, cloud computing, and cybersecurity, to assist clients in adapting to ongoing changes in the business landscape. PwC India perceives the forthcoming five years as a crucial time for the country to influence its future, aligning its goals with the broader national vision of 'Kal Ka Bharat.' The firm's strategy aims to support India's development while pursuing its own growth. The firm plans to allocate 1% of its revenues to employee training and development. It is also looking to expand its operations into Tier 2 and 3 cities, focusing on sector-specific and digital skills to promote local economic growth. Additionally, PwC India aims to enhance its social contributions through the PwC India Foundation, with a target to impact more than 500,000 lives by 2030. The firm's growth strategy is centred around six primary sectors: financial services, healthcare, industrial manufacturing, automotive, technology, and media and telecom. These sectors are seen as having significant potential for transformative change. PwC India will also explore emerging sectors to establish an early foothold. The firm acknowledges that future success will require significant changes in business models and operations. As such, it is transitioning from a traditional service provider to a more modern, delivery-oriented organisation, leveraging sector expertise and advanced technologies. Continued investment in regional delivery centres and centres of excellence is part of this strategy, aimed at improving service delivery for both domestic and international clients. With operations in all major Indian cities, nearly 900 partners, and a workforce of 30,000, PwC India is focused on maintaining a steady growth trajectory, having experienced consistent growth over the past four years. "PwC India plans to create 20,000 additional jobs in next five years" was originally created and published by International Accounting Bulletin, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
